cardiac failure as a bridge to transplant in critically ill patients. Although we often hear about the indignity of death, where resuscitation may be performed on the hopelessly ill without a chance for recovery we are now confronted with the occasional patient in whom LVAD, RVAD, or even total artificial heart may be considered as a bridge to do something.
More subtle, perhaps, is the application of the most intensive forms of health care treatment modalities to patients with diseases for whom we clearly know the prognosis is hopeless. For example, patients in their 70s and 80s with a ruptured abdominal aneurysm, renal shutdown, and shock have had almost a 100 percent fatality rate with operation, yet any patient who comes into the emergency room with this diagnosis usually receives the ultimate in intensive care, the most intensive operative intervention, long-term respirator therapy, and costly hospitalization. Will younger patients with more salvageable disease and better long-term prognosis, as acutely ill, go untreated because facilities are lacking in a particular facility, having treated the hopeless older patient?
Prolonging hopeless cases is, of course, often related to defensive medicine, that is, those tests and procedures that physicians and hospitals perform in lieu of making reasonable judgments about patients for fear they will be liable for legal action at some later date. • Usual dosage of 2.5 mg tid or qid for patients 12 years of age and older.
• 40-dose (20 ml) bottle is ideal for home use.
• Sulfite-free formulation minimizes potential for preservative-induced reactions.
•Potency expressed as albuterol. CONTRAINDICATIONS: VENTOLIN* Solution for Inhalation is contraindicated in patients with a history of hypersensitivity to any of its components.
WARNINGS:
As with other inhaled beta-adrenergic agonists, VENTOLIN3 Solution for Inhalation can produce paradoxical bronchospasm that can be life-threatening. If it occurs, the preparation should be discontinued immediately and alternative therapy instituted.
Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs and with the home use of nebulizers. It is therefore essential that the physician instruct the patient in the need for further evaluation if his/her asthma becomes worse. In individual patients, any beta;-adrenergic agonist, including albuterol solution for inhalation, may have a clinically significant cardiac effect.
Immediate hypersensitivity reactions may occur after administration of albuterol, as demonstrated by rare cases of urticaria, angioedema. rash, bronchospasm. and oropharyngeal edema. Albuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of albuterol on the vascular system may be potentiated.
Beta-receptor blocking agents and albuterol inhibit the effect of each other. Carcinogenesis, Mutagenesis, Impairment of Fertility: Albuterol sulfate, like other agents in its class, caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium in a two-year study in the rat, at oral doses corresponding to 10, 50. and 250 times the maximum human nebulizer dose In another study, this effect was blocked by the coadministration of propranolol. The relevance of these findings to humans is not known. An 18-month study in mice and a lifetime study in hamsters revealed no evidence of tumongenicity. Studies with albuterol revealed no evidence ot mutagenesis. Reproduction studies in rats revealed no evidence of impaired fertility.
Pregnancy: Teratogenic Effects: Pregnancy Category C: Albuterol has been shown to be teratogenic in mice when given subcutaneously in doses corresponding to the human nebuiization dose. There are no adequate and wellcontroi led studies in pregnant women. Albuterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. A reproduction study in CD-I mice with albuterol (0.025,0.25. and 2.5 mg/kg subcutaneously, corresponding to 0.1,1. and 12.5 times the maximum human nebuiization dose, respectively) showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. None was observed at 0.025 mg/kg. Cleft palate also occurred in 22 of 72 (30.5%) fetuses treated with 2 5 mg/kg isoproterenol (positive control). A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses at 50 mg/kg, corresponding to 250 times the maximum human nebuiization dose.
Labor and Delivery: Oral albuterol has been shown to delay preterm labor in some reports There are presently no well-controlled studies that demonstrate that it will stop preterm labor or prevent labor at term. Therefore, cautious use of VENTOLIN^ (albuterol sulfate) Solution for Inhalation is required in pregnant patients when given for relief of bronchospasm so as to avoid interference with uterine contractility. Nursing Mothers: It is not known whether this drug is excreted in human milk. Because of the potential for tumongenicity shown for albuterol in some animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use: Safety and effectiveness in children below 12 years of age have not been established.
ADVERSE REACTIONS: The results of clinical trials with VENTOLIN* Solution for Inhalation in 135 patients
showed the following side effects that were considered probably or possibly drug-related:
Central Nervous System: Tremor (20%). dizziness (7%). nervousness (4%). headache (3%). and insomnia (1%).

Gastrointestinal: Nausea (4%). dyspepsia (1%).
Ear, Nose. andThroal: Pharyngitis (<1%) and nasal congestion (1%).
Cardiovascular: Tachycardia (1%). hypertension (1%).
Respiratory: Bronchospasm (8%), cough (4%), bronchitis (4%), wheezing (1%).
No clinically relevant laboratory abnormalities related to VENTOLIN Solution for Inhalation administration were determined in these studies. 
•Estimate
Source: Uwe Reinhardt Sep 29, 1987.) many authors, the vast majority of dollars spent in intensive care is spent on nonsurvivors.
To maintain our high standard of high-tech health care we must find some way to reduce the cost without reducing the quality. Your President, with the Government Liaison Committee of ACCP, was privileged to meet with some of the advisors to the Congress on the DRG system (PROPAC), and it was evident that in the year since this system was instituted, some hospitals, particularly those specializing in high-tech health care, have done well because of the "unbundling" of hightech health services and the implementation of increasingly new and sophisticated technology, which the government has as yet seen fit to reimburse reasonably well. It may, however, soon change so that some of the costs of these services may not be fully reimbursed under new DRG levels.
We must work within the system while seeking to change it. For example, the Society of Thoracic Sur- experimental high-tech health care areas, such as the artificial heart, we need controlled regional utilization until efficacy is proved and costs reduced. We must also push manufacturers of medical devices and drugs to become more cost conscious than ever, and we must teach our students, residents, and colleagues to be cost conscious and responsible for the public every practice day.
DELIVERY OF HIGH-TECH HEALTH CARE
In addition to ethics and cost concerns, a problem in the delivery of high-tech health care is now a major public issue. As more patients require critical care, the shortage of critical care nursing personnel grows. dilemmas of medicine will increase, and more elderly patients will require maximal care. We need to prepare our hospitals with data to fall back on and prognosticate. We will be continually involved with the people who pay the cost of medical care to reduce this cost.
Physicians, surgeons, nurses, and other health care specialists will have to become actively involved in the process to reduce cost while maintaining quality of care, or we will be totally and irrevocably bypassed by third-party payers, the federal government, and the public. Malpractice insurance and the contingency fee system is an insidious and very serious cost-raising device in this country and must be limited for reductions in overall healthcare costs. Finally, we are facing a critical shortage of intensive care unit nurses and other paramedical personnel. If the nursing profession is to maintain its leadership role in the care of the intensely ill patient, it must adapt, change, evolve, and restructure its thinking to provide appropriate levels of woman/manpower. Physicians in these areas adopt a more collaborative attitude toward nurse professionals, so that we may both provide the public the very best in high-technology medicine and surgery.
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